Clinical Trial Update: Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating enzalutamide in combination with PSA-TRICOM in non-metastatic castration-sensitive prostate cancer has completed with posted res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)
• PSA-TRICOM (PSA-TRICOM)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-09-16